Prostate Cancer

University of Texas lab study finds Phellodendron tree extract inhibits prostate cancer cell growth

Published in Cancer Weekly, August 22nd, 2006

Next Pharmaceuticals, Inc. announced the results of a study funded by the U.S. National Institutes of Health on the potential benefits of Nexrutine, a proprietary extract from the bark of the Phellodendron tree, on prostate cancer.

Scientists led by principal investigator Pratap Kumar at the Department of Urology, University of Texas Health Science Center, San Antonio, Texas, have found that the herbal extract prevents the growth of prostate cancer cells in laboratory studies. The studies also found that blocking the activation of a transcription factor called CREB and a critical cell survival signaling kinase called Akt disrupted prostate cancer cell growth and induced...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2006-08-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry